Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PURVI KOTHARI MEHRA

Allopathic & Osteopathic Physicians Internal Medicine Allergy & Immunology

NPI
1336280031
CMS profile
15061
Location
SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$2,287.71

32 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,661.01 8
Food and Beverage $576.70 23
Honoraria $50.00 1

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $1,614.18 12
Eli Lilly and Company $464.42 17
Novo Nordisk AS $136.66 1
Flexion Therapeutics, Inc. $50.00 1
GlaxoSmithKline, LLC. $22.45 1

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PURVI KOTHARI MEHRA

NPI 1336280031 · CMS profile ID 15061

Allopathic & Osteopathic Physicians / Internal Medicine / Allergy & Immunology

SAN DIEGO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336280031?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PURVI KOTHARI MEHRA, NPI 1336280031, CMS profile ID 15061. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336280031?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). PURVI KOTHARI MEHRA, NPI 1336280031, CMS profile ID 15061. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336280031?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
PURVI KOTHARI MEHRA, NPI 1336280031, CMS profile ID 15061, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–32 of 32 matching records. This page contains 32 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1336280031?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

32 matching records · $2,287.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 32 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–32 of 32.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $22.4507/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670915843 CMS
Eli Lilly and Company $8.3506/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709012135 CMS
Eli Lilly and Company $4.6406/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709013675 CMS
Eli Lilly and Company $18.5606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709014159 CMS
Eli Lilly and Company $3.3406/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709014515 CMS
Eli Lilly and Company $4.6406/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709014857 CMS
Eli Lilly and Company $25.9906/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709015171 CMS
Eli Lilly and Company $44.5506/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709015173 CMS
Eli Lilly and Company $18.5606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709015175 CMS
Eli Lilly and Company $33.4106/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709015337 CMS
Eli Lilly and Company $136.9806/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709015339 CMS
Eli Lilly and Company $1.8606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709016879 CMS
Eli Lilly and Company $4.4606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709016881 CMS
Eli Lilly and Company $11.1406/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709016883 CMS
Eli Lilly and Company $1.8606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709016885 CMS
Eli Lilly and Company $2.6006/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709017571 CMS
Eli Lilly and Company $6.5006/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709017573 CMS
Eli Lilly and Company $136.9806/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 709017575 CMS
Novo Nordisk AS $136.6606/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703544125 CMS
Merck Sharp & Dohme Corporation $13.9105/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804301 CMS
Merck Sharp & Dohme Corporation $30.8205/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804747 CMS
Merck Sharp & Dohme Corporation $78.4105/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695805031 CMS
Merck Sharp & Dohme Corporation $103.1305/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804299 CMS
Merck Sharp & Dohme Corporation $24.9905/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804585 CMS
Merck Sharp & Dohme Corporation $247.0605/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804745 CMS
Merck Sharp & Dohme Corporation $50.0005/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804749 CMS
Merck Sharp & Dohme Corporation $81.1905/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695805033 CMS
Merck Sharp & Dohme Corporation $209.0005/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804583 CMS
Merck Sharp & Dohme Corporation $247.0605/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804743 CMS
Merck Sharp & Dohme Corporation $502.3905/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695804751 CMS
Merck Sharp & Dohme Corporation $26.2205/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695806407 CMS
Flexion Therapeutics, Inc. $50.0001/08/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705866853 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,287.71 32

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019
Generated from
OP_DTL_GNRL_PGYR2019_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Recipient $375.00 2
PY2022 Principal investigator $30,891.10 5
PY2021 Principal investigator $3,333,813.44 59
PY2020 Recipient $3,034.66 5
PY2020 Principal investigator $1,118,926.99 96
PY2019 Recipient $6,389.04 5
PY2019 Principal investigator $1,783,635.66 134

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

59 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $27,131.47 12/31/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of the Concomitant Administration of Either 23-Valent Pneumococcal Polysaccharide Vaccine or 15-Valent Pneumococcal Conjugate Vaccine with a Booster Dose of SARS-CoV-2 mRNA Vaccine in Healthy Adults 50 Years of Age or Older. No dispute reported 06/30/2026 848764847
Principal investigator 1 Merck Sharp & Dohme LLC $981.41 12/31/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU FLU No dispute reported 06/30/2026 937746039
Principal investigator 1 PFIZER INC. $1,500.00 10/14/2021 Non-covered Recipient Entity
Artemis Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832862579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $116,086.39 10/07/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793111563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $106,322.27 09/16/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793109901
Principal investigator 1 Janssen Research & Development, LLC $46,713.00 09/01/2021 Non-covered Recipient Entity
Artemis Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787619209
Principal investigator 1 PFIZER INC. $283.96 08/06/2021 Non-covered Recipient Entity
Artemis Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832765983
Principal investigator 1 PFIZER INC. $283.96 07/21/2021 Non-covered Recipient Entity
Artemis Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832703379
Principal investigator 1 Janssen Research & Development, LLC $67,991.00 07/14/2021 Non-covered Recipient Entity
Artemis Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787619229
Principal investigator 1 PFIZER INC. $283.96 07/09/2021 Non-covered Recipient Entity
Artemis Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832768309
Principal investigator 1 Janssen Research & Development, LLC $27,866.00 06/25/2021 Non-covered Recipient Entity
Artemis Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787619126
Principal investigator 1 PFIZER INC. $3,691.48 06/23/2021 Non-covered Recipient Entity
Artemis Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832768299
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $122.63 06/23/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793104707
Principal investigator 1 Janssen Research & Development, LLC $3,000.00 06/18/2021 Non-covered Recipient Entity
Artemis Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787619109
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $23,207.18 06/17/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851025215
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $500.00 06/17/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851025271
Principal investigator 1 Janssen Research & Development, LLC $24,021.00 06/16/2021 Non-covered Recipient Entity
Artemis Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787619093
Principal investigator 1 PFIZER INC. $283.96 06/09/2021 Non-covered Recipient Entity
Artemis Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832900937
Principal investigator 1 Novo Nordisk AS $500.00 05/26/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 811867485
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,901.20 05/25/2021 Non-covered Recipient Entity
Artemis Institute For Clinical Research - San Marcos
A Multi-Center, Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Phase 3 Study With Randomized Withdrawal and Retreatment to Evaluate the Efficacy and Safety of BMS-986165 in Subjects With Moderate-to-Severe Plaque Psoriasis No dispute reported 06/30/2026 819891529
Principal investigator 1 Janssen Research & Development, LLC $197,932.00 05/25/2021 Non-covered Recipient Entity
Artemis Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787619075
Principal investigator 1 Janssen Research & Development, LLC $120,771.00 05/21/2021 Non-covered Recipient Entity
Artemis Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787619059
Principal investigator 1 PFIZER INC. $3,975.44 05/21/2021 Non-covered Recipient Entity
Artemis Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832769257
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $122.63 05/21/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793102795
Principal investigator 1 PFIZER INC. $7,099.00 05/07/2021 Non-covered Recipient Entity
Artemis Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832692757
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $122.63 04/28/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793101677
Principal investigator 1 Janssen Research & Development, LLC $400,365.00 04/27/2021 Non-covered Recipient Entity
Artemis Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787619041
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,336.40 04/22/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 806254355
Principal investigator 1 PFIZER INC. $567.92 04/21/2021 Non-covered Recipient Entity
Artemis Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832842937
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $164.25 04/16/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793101025
Principal investigator 1 Novo Nordisk AS $2,465.25 03/31/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 811338905
Principal investigator 1 Janssen Research & Development, LLC $662,895.00 03/24/2021 Non-covered Recipient Entity
Artemis Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787619021
Principal investigator 1 Novo Nordisk AS $1,000.00 03/24/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 811839549
Principal investigator 1 Novo Nordisk AS $1,000.00 03/24/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
NN9535-4506 No dispute reported 06/30/2026 811839551
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 03/19/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793099147
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,250.00 03/19/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793099155
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $164.25 03/18/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793098835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $245.26 03/18/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793098839
Principal investigator 1 Eli Lilly and Company $245,165.00 03/16/2021 Non-covered Recipient Entity
ARTEMIS HEADLANDS LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 819450357
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $75.00 03/11/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793098207
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,430.00 03/11/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793098211
Principal investigator 1 Janssen Research & Development, LLC $676,220.00 02/23/2021 Non-covered Recipient Entity
Artemis Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787619005
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $164.25 02/18/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793095539
Principal investigator 1 PFIZER INC. $3,652.18 02/17/2021 Non-covered Recipient Entity
Artemis Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832847463
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $1,701.00 02/11/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851021817
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $18,436.98 02/09/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof of Concept Study of the Efficacy and Safety of Fremanezumab for Treatment of Patients With Fibromyalgia No dispute reported 06/30/2026 806254267
Principal investigator 1 PFIZER INC. $381.71 02/05/2021 Non-covered Recipient Entity
Artemis Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832856101
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $122.63 02/05/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793094115
Principal investigator 1 Janssen Research & Development, LLC $23,442.00 02/02/2021 Non-covered Recipient Entity
Artemis Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787618989
Principal investigator 1 Eli Lilly and Company $101.90 01/29/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 819451697
Principal investigator 1 Janssen Research & Development, LLC $438,208.00 01/26/2021 Non-covered Recipient Entity
Artemis Clinic Rsrch
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787618969
Principal investigator 1 Eli Lilly and Company $4,000.00 01/25/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3, RANDOMIZED, OPEN-LABEL TRIAL COMPARING EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS SEMAGLUTIDE ONCE WEEKLY AS ADD-ON THERAPY TO METFORMIN IN PATIENTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 819452485
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $13,609.36 01/21/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793092567
Principal investigator 1 PFIZER INC. $14,036.82 01/16/2021 Non-covered Recipient Entity
Artemis Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832761453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,669.40 01/15/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO AND NAPROXEN-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793091973
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $7,125.00 01/14/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851019635
Principal investigator 1 Biohaven Pharmaceuticals, Inc. $3,875.85 01/14/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH
A Phase 2/3 Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant in Migraine Prevention No dispute reported 06/30/2026 851020027
Principal investigator 1 PFIZER INC. $3,126.83 01/09/2021 Non-covered Recipient Entity
Artemis Headlands LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE 20VPNC WHEN COADMINISTERED WITH SEASONAL INACTIVATED INFLUENZA VACCINE SIIV IN ADULTS 65 YEARS OF AGE No dispute reported 06/30/2026 832765989
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $122.63 01/07/2021 Non-covered Recipient Entity
ARTEMIS INSTITUTE FOR CLINICAL RESEARCH LLC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, MULTI-DOSE, PLACEBO-CONTROLLED STUDY TO EVALUATE THE LONG-TERM SAFETY AND THE EFFICACY OF FASINUMAB IN PATIENTS WITH PAIN DUE TO OSTEOARTHRITIS OF THE KNEE OR HIP No dispute reported 06/30/2026 793091615